Latest News
- Drug combination domino effect destroys pancreatic cancer cells
Cancer Research UK scientists have revealed how a combination of two very different drugs, currently being tested in clinical trials, amplifies the destruction of pancreatic cancer cells, according to research published in the Journal of Experimental Medicine, today (Monday). - Convergence Pharmaceuticals announces start of Phase II study for CNV1014802
Convergence Pharmaceuticals today announced that the Phase II proof of concept study with CNV1014802 for treating pain associated with lumbosacral radiculopathy (LSR) has started. - Mental health problems after miscarriage continue after healthy birth
Women who experience depression and anxiety after a miscarriage continue to experience these symptoms even if they subsequently go on to have a healthy child. - AstraZeneca and Pfizer Join Cancer Research UK’s Stratified Medicine Programme
CANCER RESEARCH UK will be supported by AstraZeneca and Pfizer in a multimillion pound initiative to examine how genetic tests to improve cancer diagnosis can be best rolled out across the NHS.Cancer Research UK’s pioneering “Stratified Medicine Programme”* will also promote research into new targeted treatments by building a database of genetic information about tumours, treatments and survival rates that will enable researchers to design more effective cancer treatments in future. - GSK and Prosensa announce start of Phase III study of investigational Duchenne Muscular Dystrophy medication
GlaxoSmithKline (GSK) and Prosensa today announced that the first patient has commenced treatment in the Phase III study investigating GSK2402968, in ambulant boys with Duchenne Muscular Dystrophy (DMD), who have a dystrophin gene mutation amenable to an exon 51 skip
No comments:
Post a Comment